Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity
about
Increase of malaria attacks among children presenting concomitant infection by Schistosoma mansoni in SenegalPreclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxEpidemiology of plasmodium-helminth co-infection in Africa: populations at risk, potential impact on anemia, and prospects for combining controlMalaria and helminth interactions in humans: an epidemiological viewpointA malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparumCan follicular helper T cells be targeted to improve vaccine efficacy?Discovery of a novel and conserved Plasmodium falciparum exported protein that is important for adhesion of PfEMP1 at the surface of infected erythrocytesA conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparumMalaria Parasites: The Great EscapeToward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans.Clag9 is not essential for PfEMP1 surface expression in non-cytoadherent Plasmodium falciparum parasites with a chromosome 9 deletion.Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.Helminth infection and eosinophilia and the risk of Plasmodium falciparum malaria in 1- to 6-year-old children in a malaria endemic area.Effect of treating Schistosoma haematobium infection on Plasmodium falciparum-specific antibody responses.Heritability of antibody isotype and subclass responses to Plasmodium falciparum antigensSafety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe childrenUnderstanding human-Plasmodium falciparum immune interactions uncovers the immunological role of worms.IL4 gene polymorphism and previous malaria experiences manipulate anti-Plasmodium falciparum antibody isotype profiles in complicated and uncomplicated malaria.Isotypic analysis of Plasmodium falciparum-specific antibodies and their relation to protection in Madagascar.Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohortAnalysis of inhibitory epitopes in the Plasmodium falciparum rhoptry protein RAP-1 including identification of a second inhibitory epitopeImpact of schistosome infection on Plasmodium falciparum Malariometric indices and immune correlates in school age children in Burma Valley, Zimbabwe.Antigenicity of recombinant proteins derived from rhoptry-associated protein 1 of Plasmodium falciparum.Induction of protective immune responses by immunization with linear multiepitope peptides based on conserved sequences from Plasmodium falciparum antigensLevels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria.Interethnic differences in antigen-presenting cell activation and TLR responses in Malian children during Plasmodium falciparum malaria.Allelic diversity and antibody recognition of Plasmodium falciparum merozoite surface protein 1 during hypoendemic malaria transmission in the Brazilian amazon region.High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria.Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam.Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity.Assessment of the effect of Schistosoma haematobium co infection on malaria parasites and immune responses in rural populations in Gabon: study protocol.Evaluation of naturally acquired IgG antibodies to a chimeric and non-chimeric recombinant species of Plasmodium vivax reticulocyte binding protein-1: lack of association with HLA-DRB1*/DQB1* in malaria exposed individuals from the Brazilian Amazon.Regulation of antigen-specific immunoglobulin G subclasses in response to conserved and polymorphic Plasmodium falciparum antigens in an in vitro modelAssociations between responses to the rhoptry-associated membrane antigen of Plasmodium falciparum and immunity to malaria infectionPhase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureNatural human antibody responses to Plasmodium vivax apical membrane antigen 1 under low transmission and unstable malaria conditions in Sri Lanka.Anti-malarial market and policy surveys in sub-Saharan AfricaSubclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria.Analysis of human antibodies to erythrocyte binding antigen 175 peptide 4 of Plasmodium falciparum.
P2860
Q21033747-42AC1D5D-EC8D-4C8E-AE05-E17C3CA9F043Q24273364-A7083807-2D53-4083-8EFD-C2DB63B256CFQ24656072-519D039F-2D00-45EE-B918-2D79575BC7EFQ24677835-23DDF194-79A2-4EC4-A63D-13E9CBB7A0F8Q24814432-E9747AE7-73B5-4CB0-94A2-8D58BB6A8301Q26753848-37960B59-A567-4BE0-9B8D-2EC60766DE66Q27974160-A28EDD5F-B45B-4920-BA55-182FBA11B2B0Q27974528-F18304EE-20EE-4453-8F97-E91C171A7B56Q28080325-D19E4DBD-F6FE-4E93-AED9-9176184BE5ACQ30492536-86FA9F29-80E5-4A6F-BD90-33BF477B1878Q31044131-9A102BE6-D0A4-4611-81D6-BF6209BF4E9AQ33305467-A35E42E6-E4D9-4C9F-94D9-9C51987236B2Q33319239-FDE9A8AF-E01A-4625-97A8-E11517D62BDDQ33385010-02E0FCA0-227E-4024-AA24-E9A6EF518DEAQ33509282-27929582-BAB2-484A-B7C9-018EDB496879Q33512533-0BE7B5C6-1895-46D4-8386-B1AE79A41561Q33533310-5EEDB90F-739D-475B-90BC-9409804B083AQ33562843-62E7D233-BB61-4CE0-9523-61BA54CBA94EQ33612549-0C3A94D2-648F-437E-8722-D33BA5A60926Q33621604-303B9156-9694-40E4-B608-98E7937B7610Q33749504-3D077647-8D86-42B6-9924-34374371257DQ33749755-1CEFA062-00F9-454B-8BBC-B7768CDC2C39Q33751469-D3B2A328-3EDF-46B6-A289-BDE543EF7CB6Q33756304-CE9F97E6-E890-4FDF-8751-43F5DD1DA523Q33866742-694F1F20-4ECF-45DC-81DC-1D837B6FC912Q33869738-9E423EC4-8DC9-42BC-96AE-78B6661FA478Q34002481-B5B20196-D0B0-406C-B6F6-F3CC1A64F6E8Q34003525-9528320D-7077-4EB8-9640-D3B2F886D621Q34008262-9D77EC2B-A010-42C7-9663-B98AFFB4B49DQ34008755-5E03F66E-B067-4FD9-9C47-802032F43F76Q34028797-767850F9-AAFE-4339-9EC5-527BE76CD6C1Q34078790-9EBA61C0-7038-481F-81EA-BB0C6C05FA0CQ34123317-CCACB661-8EFF-4709-BE96-4ECDF77DCB1BQ34145697-FEC7B5EE-E294-459E-BDC6-DCCAADB192BFQ34194609-04C4967F-AC77-4A03-87E1-4B7CCD5C4AB2Q34257253-50B3949A-2F88-4AB1-BF18-1C53C8821714Q34301073-085666C5-05CA-44C3-B58F-9C18B7CED5E1Q34407223-5C6B8298-2CC3-4993-9D07-808512AEA732Q34515219-09F6D19E-3416-4BBF-B1C8-8928CC10ECE8Q34537136-C20DA299-D2A2-4DDC-9D5B-E8904F896DBB
P2860
Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Plasmodium falciparum malaria: ...... isition of protective immunity
@en
type
label
Plasmodium falciparum malaria: ...... isition of protective immunity
@en
prefLabel
Plasmodium falciparum malaria: ...... isition of protective immunity
@en
P2860
P1476
Plasmodium falciparum malaria: ...... isition of protective immunity
@en
P2093
Bouharoun-Tayoun H
P2860
P304
P407
P577
1992-04-01T00:00:00Z